@inproceedings{farzana-etal-2024-slacad,
    title = "{SL}a{CAD}: A Spoken Language Corpus for Early {A}lzheimer{'}s Disease Detection",
    author = "Farzana, Shahla  and
      Stoppa, Edoardo  and
      Leow, Alex  and
      Gollan, Tamar  and
      Moore, Raeanne  and
      Salmon, David  and
      Galasko, Douglas  and
      Sundermann, Erin  and
      Parde, Natalie",
    editor = "Calzolari, Nicoletta  and
      Kan, Min-Yen  and
      Hoste, Veronique  and
      Lenci, Alessandro  and
      Sakti, Sakriani  and
      Xue, Nianwen",
    booktitle = "Proceedings of the 2024 Joint International Conference on Computational Linguistics, Language Resources and Evaluation (LREC-COLING 2024)",
    month = may,
    year = "2024",
    address = "Torino, Italia",
    publisher = "ELRA and ICCL",
    url = "https://aclanthology.org/2024.lrec-main.1296",
    pages = "14877--14897",
    abstract = "Identifying early markers of Alzheimer{'}s disease (AD) trajectory enables intervention in early disease stages when our currently-available interventions are most likely to be beneficial. Research has shown that alterations in speech, as well as linguistic and semantic deviations in spontaneous conversation detected using natural language processing, manifest early in AD prior to some other observed cognitive deficits. Recent studies show that cerebrospinal fluid (CSF) levels serve as useful early biomarkers for identifying early AD, but CSF biomarkers are challenging to collect. A simpler alternative that has seen very rapid development is based on the use of plasma biomarkers as a blood draw is minimally invasive. Associating verbal and nonverbal characteristics from speech data with CSF and plasma biomarkers may open the door to less invasive, more efficient methods for early AD detection. We present SLaCAD, a new dataset to facilitate this process. We describe our data collection procedures, analyze the resulting corpus, and present preliminary findings that relate measures extracted from the audio and transcribed text to clinical diagnoses, CSF levels, and plasma biomarkers. Our findings demonstrate the feasibility of this and indicate that the collected data can be used to improve assessments of early AD.",
}

Identifying early markers of Alzheimer{'}s disease (AD) trajectory enables intervention in early disease stages when our currently-available interventions are most likely to be beneficial. Research has shown that alterations in speech, as well as linguistic and semantic deviations in spontaneous conversation detected using natural language processing, manifest early in AD prior to some other observed cognitive deficits. Recent studies show that cerebrospinal fluid (CSF) levels serve as useful early biomarkers for identifying early AD, but CSF biomarkers are challenging to collect. A simpler alternative that has seen very rapid development is based on the use of plasma biomarkers as a blood draw is minimally invasive. Associating verbal and nonverbal characteristics from speech data with CSF and plasma biomarkers may open the door to less invasive, more efficient methods for early AD detection. We present SLaCAD, a new dataset to facilitate this process. We describe our data collection procedures, analyze the resulting corpus, and present preliminary findings that relate measures extracted from the audio and transcribed text to clinical diagnoses, CSF levels, and plasma biomarkers. Our findings demonstrate the feasibility of this and indicate that the collected data can be used to improve assessments of early AD.
Farzana, Shahla Stoppa, Edoardo Leow, Alex Gollan, Tamar Moore, Raeanne Salmon, David Galasko, Douglas Sundermann, Erin Parde, Natalie
SLaCAD: A Spoken Language Corpus for Early Alzheimer's Disease Detection